Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4976139 | 0.81 | CA12 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28158455 | 0.80 | CA1 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29352597 | 0.77 | CA12 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL83318 | 0.77 | CA12 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28017835 | 0.77 | HPGD (0.36) | MEN1MAPTKMT2AGAAHPGD | |
| SCHEMBL232793 | 0.76 | CA12 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL10891995 | 0.76 | NQO1 (0.52) | CA12CA1CA7CA9CA14 | |
| SCHEMBL29096230 | 0.75 | CA12 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL16956115 | 0.74 | ALDH1A1 (0.43) | CA12CA1CA2CA7CA9 | |
| SCHEMBL687956 | 0.74 | CA12 (0.48) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9745288-B2 | Compounds and methods for treating cancer by inhibiting the urokinase receptor | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2017-08-29 | — | — | US | claimed |
| US-20150051247-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER BY INHIBITING THE UROKINASE RECEPTOR | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2015-02-19 | — | — | US | claimed |
| WO-2013025939-A2 | COMPOUNDS AND METHODS FOR TREATING CANCER BY INHIBITING THE UROKINASE RECEPTOR | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2013-02-21 | — | — | WO | claimed |
| EP-3641776-A1 | ATROPISOMERISM FOR ENHANCED KINASE INHIBITOR SELECTIVITY | San Diego State University Research Foundation (US) | 2020-04-29 | — | — | EP | disclosed |
| WO-2018237134-A1 | ATROPISOMERISM FOR ENHANCED KINASE INHIBITOR SELECTIVITY | SAN DIEGO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2018-12-27 | — | — | WO | disclosed |
| US-9745288-B2 | Compounds and methods for treating cancer by inhibiting the urokinase receptor | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| EP-2900645-A1 | 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION | Bayer CropScience AG (DE) | 2015-08-05 | — | — | EP | disclosed |
| US-20150051247-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER BY INHIBITING THE UROKINASE RECEPTOR | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2015-02-19 | — | — | US | disclosed |
| WO-2013025939-A2 | COMPOUNDS AND METHODS FOR TREATING CANCER BY INHIBITING THE UROKINASE RECEPTOR | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051247-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER BY INHIBITING THE UROKINASE RECEPTOR | PLAUR, PLAU, PLG | CA12 873/4885CA1 959/4885CA2 1782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.